Gonadorelin

Source-reported examples · not treatment recommendations

Amount

50–200 micrograms per administration

Frequency

Two or three times weekly in the main example

Cycle / observation period

4–8 weeks; source limits its separate daily example to 14 days

Route / research model

Subcutaneous

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• Gonadorelin is synthetic gonadotropin-releasing hormone, commonly abbreviated GnRH. Research involving this hormone covers different questions: whether the pituitary responds to stimulation, whether carefully timed treatment can restore ovulation in selected patients, and whether treatment leads to pregnancy or live birth. Those outcomes should not be combined into a general claim of hormonal optimization. ^[1]
• A 1986 study examined gonadorelin responses in 11 normally cycling women and 10 women with secondary amenorrhea. The investigators measured LH and FSH after stimulation, with a particularly marked LH response. A second challenge did not produce a larger relative increment. This was a hormone-response experiment, not a trial establishing sustained fertility benefit. ^[1]
• No. That was the reported live-birth rate per treatment in the selected retrospective cohort described above. Applying it to an unrelated individual would exceed what the study establishes. ^[4]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 15 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. Original gonadorelin stimulation study
2. Endocrine Society brain-hormone resource
3. Hypopituitarism guideline, recommendation 1.15
4. Quaas and colleagues, original cohort
5. Functional hypothalamic amenorrhea guideline
6. PubMedFurther reading · Listed in reference bibliography.
7. Mayo ClinicGeneral guidance · Listed in reference bibliography.
8. WikipediaFurther reading · Listed in reference bibliography.
9. PMCFurther reading · Listed in reference bibliography.
10. PubMedFurther reading · Listed in reference bibliography.
11. ScienceDirectFurther reading · Listed in reference bibliography.
12. PMCFurther reading · Listed in reference bibliography.
13. PMCFurther reading · Listed in reference bibliography.
14. PubMedFurther reading · Listed in reference bibliography.
15. Drugs.comFurther reading · Listed in reference bibliography.
16. PMCFurther reading · Listed in reference bibliography.
17. CDCGeneral guidance · Listed in reference bibliography.
18. CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
19. NCBI BookshelfFurther reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.